AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02977507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica Facial Cleanser
Description: SkinMedica facial cleanser applied to the face as directed.
Study NCT02977507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SkinMedica Rejuvenative Moisturizer
Description: SkinMedica rejuvenative moisturizer applied to the face as directed.
Study NCT02977507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica Rejuvenative Moisturizer
Description: SkinMedica rejuvenative moisturizer applied to the face as directed.
Study NCT02977507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
Description: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
Study NCT02977507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
Description: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
Study NCT02438761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression.
Study NCT00633360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone and ethinyl estradiol
Description: Once daily by mouth
Study NCT00633360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily by mouth
Study NCT02219737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IVPB
Study NCT02219737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IVPB
Study NCT02219737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02219737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT02219737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02219737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02219737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03030014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational programm
Description: Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
Study NCT03030014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no educational program
Description: without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
Study NCT01505114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300-mg tablet, once daily, from Week 0 through Week 48
Study NCT01505114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200-mg capsule, once daily, from Week 0 through Week 48
Study NCT01505114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300-mg tablet, once daily, from Week 0 through Week 48
Study NCT01505114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maraviroc placebo
Description: Once daily from Week 0 through Week 48
Study NCT01505114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emtricitabine placebo
Description: Once daily from Week 0 through Week 48
Study NCT01505114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate placebo
Description: Once daily from Week 0 through Week 48
Study NCT04967911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic stabilization exercises
Description: PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
Study NCT04967911 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
Study NCT03837197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liver-Hypothermic oxygenated
Description: Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers.
Study NCT03310879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
Study NCT02770560 — intervention group
Intervention type: DEVICE
Intervention: Urokinase locking solution
Description: On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
Study NCT04144244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MicroFluidic Sperm Sorting Chips
Description: sperm selection of IUI treatment
Study NCT04144244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradient-Density Centrifugation
Description: sperm selection of IUI treatment
Study NCT01850771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenexx PL-Disc
Description: Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
Study NCT01850771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Epidural
Description: Injection into the epidural space under image guidance of 3 mg of betamethasone.
Study NCT01666574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test cereal 1, Oat-based
Description: The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
Study NCT01666574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Cereal 2, Oat based
Description: The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
Study NCT00534560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabersat
Description: Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
Study NCT00534560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabersat
Description: Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
Study NCT00534560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets; 4 week dose titration with 16 weeks at target dose
Study NCT02228460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ/SAR402671
Description: Pharmaceutical form: Capsule; Route of administration: Oral
Study NCT03090178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electronic-Patient Report Outcome and wear of a wristband actigraph
Description: Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
Study NCT03090178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic-Patient Report Outcome and wear of a wristband actigraph
Description: Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
Study NCT01243892 — intervention group
Intervention type: DEVICE
Intervention: NuSpin
Description: Device for administration of doses of somatropin.
Study NCT01243892 — intervention group
Intervention type: DRUG
Intervention: Somatropin
Description: Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
Study NCT05090059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower limb myofascial trigger points f-ESWT
Description: 3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
Study NCT05090059 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lower limb myofascial trigger points f-ESWT
Description: 3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
Study NCT04302298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A machine which immerses the participant in a simulated environment where they can perform a procedure.
Study NCT02936830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Sodium Fluoride Varnish
Description: 5% sodium fluoride varnish applied on the dentin by the dentist
Study NCT02936830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% Nanohydroxyapetite paste
Description: 15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
Study NCT02936830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycerol
Description: Glycerol with water in a 1: 1 ratio
Study NCT02591069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulation device
Description: All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
Study NCT02627144 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
Study NCT02627144 — intervention group
Intervention type: DRUG
Intervention: Interferon alpha-2a
Description: Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
Study NCT02825056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
Study NCT02825056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Morphine
Description: Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
Study NCT00597181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with mitomycin c
Description: mitomycin c 0.2 mg/cc for 2 minutes
Study NCT00597181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ex-Press mini shunt with mitomycin c
Description: mitomycin c 0.2 mg/cc for 2 minutes
Study NCT03548259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma injection
Study NCT03548259 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma injection
Study NCT03548259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma
Description: Platelet-poor plasma injection
Study NCT03548259 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet-poor plasma
Description: Platelet-poor plasma injection
Study NCT04476069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBUPROFEN
Description: given to children 30 minutes before extraction / orally for one time only
Study NCT04476069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IBUPROFEN
Description: given to children 30 minutes before extraction / orally for one time only
Study NCT04357132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VR-Biofeedback
Description: Participants will be instructed to use the Mindful Aurora Application
Study NCT04357132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VR-Distraction
Description: Participants will be instructed to use one of four applications
Study NCT04547569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech adaptation
Description: Sensorimotor adaptation in speech
Study NCT04547569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vibrotactile Discrimination
Description: Vibrotactile Discrimination
Study NCT04547569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI measurement of brain activity
Study NCT04547569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech production
Description: Speech production task
Study NCT00654420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
Study NCT00654420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
Study NCT00287885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m\^2/day up to dose level 6 of 6.4 mg/m\^2/day
Study NCT02957305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 400mcg Tab
Description: 400µg of misoprostol (2 tablets)
Study NCT02957305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 200mcg Tab
Description: 200µg of misoprostol (1 tablet)
Study NCT03801291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal repair
Description: Vaginal incision through which plication of the rectovaginal septum is done
Study NCT03801291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal repair
Description: Perineal incision through which plication of the rectovaginal septum is done
Study NCT03911804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bolus group and infusion group for epidural block
Description: Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
Study NCT03911804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bolus group and infusion group for epidural block
Description: Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
Study NCT02008201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Study NCT01111097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate
Description: Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
Study NCT02137174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home and school visits
Description: Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
Study NCT04007718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation bias training
Description: Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
Study NCT04007718 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Interpretation bias training
Description: Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
Study NCT02581514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled exams and diagnosis
Description: Scheduled exams and diagnosis circuit as imposed by the algorithm
Study NCT03059602 — intervention group
Intervention type: OTHER
Intervention: No specific treatment based intervention-health measurement instrument
Description: Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
Study NCT03632304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with minimal sedation
Description: The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
Study NCT02444520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated GP Care
Description: The overall aims of the intervention are to help the patient:~1. develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;~2. understand factors that may be maintaining the problem;~3. learn how to modify the behavioral and cognitive responses which may be maintaining the problem;~4. adopt a healthy sleep routine which can promote healthy living.~Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed.